Success Metrics

Active Trials

6(75%)

Phase Distribution

Ph phase_2

63%

Ph early_phase_1

13%

Ph phase_4

13%

Ph phase_1

13%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution8 total trials

Early Phase 1First-in-human

1(12.5%)

Phase 1Safety & dosage

1(12.5%)

Phase 2Efficacy & side effects

5(62.5%)

Phase 4Post-market surveillance

1(12.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(8)

Detailed Status

Recruiting4

Active, not recruiting2

Not yet recruiting2

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

N/A

Most Advanced

Phase 4

Trials by Phase

Early Phase 11 (12.5%)

Phase 11 (12.5%)

Phase 25 (62.5%)

Phase 41 (12.5%)

Trials by Status

active_not_recruiting225%

not_yet_recruiting225%

recruiting450%

Recent Activity

6 active trials

Showing 5 of 8

active_not_recruitingphase_2

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

NCT02465060

not_yet_recruitingphase_1

A Phase 1/2 Trial Of Larotrectinib And Pembrolizumab In Patients With Solid Tumors Previously Treated With Immune Checkpoint Inhibitor Monotherapy

NCT07843550

active_not_recruitingphase_2

Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E)

NCT06390852

recruitingphase_2

Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.

NCT06563999

recruitingearly_phase_1

A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion

NCT04655404

View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials

NCT02465060Phase 2

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Active Not Recruiting

NCT07843550Phase 1

A Phase 1/2 Trial Of Larotrectinib And Pembrolizumab In Patients With Solid Tumors Previously Treated With Immune Checkpoint Inhibitor Monotherapy

Not Yet Recruiting

NCT06390852Phase 2

Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E)

Active Not Recruiting

NCT06563999Phase 2

Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.

Recruiting

NCT04655404Early Phase 1

A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion

Recruiting

NCT07010393Phase 4

Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study

Not Yet Recruiting

NCT06482086Phase 2

Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer

Recruiting

NCT05725200Phase 2

Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer

Recruiting

All 8 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 8